1880 Century Park East, Suite #315
64 articles with BriaCell
BriaCell Therapeutics Corp. announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty member.
Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.
BriaCell Therapeutics Corp. announces that its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
BriaCell Therapeutics Corp. announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer (CMO), effective today.
BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased since program commencement.
BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange as of the opening of trading on Friday, December 31, 2021.
BriaCell Therapeutics Corp. announces that certain members of its Board of Directors and Management team (the “Insiders”) have informed the Company of their intention, on an individual basis and not in concert, to use their personal funds to purchase approximately 10% of the Company’s basic common shares outstanding.
BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board
BriaCell Therapeutics Corp. announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.
BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. announces today that the Company will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually on September 29-30, 2021.
BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
BriaCell Therapeutics Corp. announces it will be present at the H.C. Wainwright 23rd Annual Global Investment Conference
BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer
BriaCell Therapeutics Corp. jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc
BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment
BriaCell Therapeutics Corp. today announces the open recruitment and enrollment of their collaborative clinical study with Incyte.
BriaCell Therapeutics Corp. today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in virtual conferences.
BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers
BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer.
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, provides an update on the overall survival data on its previously disclosed advanced breast cancer patients.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the " Shareholders ") for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp.